MX371228B - Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total. - Google Patents
Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total.Info
- Publication number
- MX371228B MX371228B MX2017015918A MX2017015918A MX371228B MX 371228 B MX371228 B MX 371228B MX 2017015918 A MX2017015918 A MX 2017015918A MX 2017015918 A MX2017015918 A MX 2017015918A MX 371228 B MX371228 B MX 371228B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibition
- diagnosis
- treatments relating
- methods
- treatments
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente invención se refiere a un anticuerpo antiperiostina capaz de detectar periostina Total, que comprende las secuencias de región hipervariable (HVR) de las secuencias de región hipervariable (HVR) de la secuencia del domino variable de la cadena pesada (VH) de SEQ ID NO: 1 y las secuencias HVR de la secuencia del dominio variable de la cadena ligera (VL) de SEQ ID NO: 2; o las secuencias HVR de la secuencia VH de SEQ ID NO: 3 y las secuencia HVR de la secuencia VL de SEQ ID NO: 4. Un kit para medir Periostina Total en una muestra biológica de un paciente, y un composición que comprende el anticuerpo antiperiostina.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45976010P | 2010-12-16 | 2010-12-16 | |
US201161465425P | 2011-03-18 | 2011-03-18 | |
US201161484650P | 2011-05-10 | 2011-05-10 | |
US201161574485P | 2011-08-02 | 2011-08-02 | |
US201161557295P | 2011-11-08 | 2011-11-08 | |
PCT/US2011/065410 WO2012083132A2 (en) | 2010-12-16 | 2011-12-16 | Diagnosis and treatments relating to th2 inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX371228B true MX371228B (es) | 2020-01-10 |
Family
ID=46234723
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015918A MX371228B (es) | 2010-12-16 | 2011-12-16 | Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total. |
MX2013006712A MX352789B (es) | 2010-12-16 | 2011-12-16 | Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006712A MX352789B (es) | 2010-12-16 | 2011-12-16 | Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio. |
Country Status (19)
Country | Link |
---|---|
US (4) | US20120156194A1 (es) |
EP (2) | EP3447491A3 (es) |
JP (4) | JP6005657B2 (es) |
KR (4) | KR101615474B1 (es) |
CN (4) | CN105175542B (es) |
AR (1) | AR084342A1 (es) |
AU (1) | AU2011343570B2 (es) |
BR (2) | BR112013013460A8 (es) |
CA (2) | CA2817380C (es) |
HK (2) | HK1215711A1 (es) |
IL (2) | IL226821B (es) |
MX (2) | MX371228B (es) |
MY (1) | MY188365A (es) |
NZ (2) | NZ609493A (es) |
RU (2) | RU2578468C2 (es) |
SG (3) | SG190885A1 (es) |
TW (4) | TWI732259B (es) |
WO (1) | WO2012083132A2 (es) |
ZA (1) | ZA201302979B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2550651C (en) | 2003-12-23 | 2018-01-23 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
MY188365A (en) | 2010-12-16 | 2021-12-06 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
MX370486B (es) * | 2012-03-27 | 2019-12-16 | Genentech Inc | Composiciones, métodos y usos para asistir en el diagnóstico, pronóstico y tratamiento de la fibrosis pulmonar idiopática. |
AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
MX2015012326A (es) | 2013-03-15 | 2016-03-08 | Genentech Inc | Anticuerpos anti-crth2 y su uso. |
WO2014151648A1 (en) * | 2013-03-15 | 2014-09-25 | Coronado Biosciences, Inc. | Treatment of autoimmune disease using helminthic parasites |
RU2703568C2 (ru) * | 2013-08-12 | 2019-10-21 | Астразенека Аб | Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба |
CN111617244A (zh) * | 2013-08-12 | 2020-09-04 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗改善哮喘症状的方法 |
CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
BR112016004413A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | composições, preparação de anticorpo e método de purificação de um polipeptídeo recombinante e de tratamento de um distúrbio |
JP6250351B2 (ja) * | 2013-09-30 | 2017-12-20 | シスメックス株式会社 | 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー |
SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
MX2016005159A (es) * | 2013-10-23 | 2016-07-05 | Genentech Inc | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. |
SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
MX2016009491A (es) | 2014-01-27 | 2017-01-13 | Medimmune Llc | Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. |
EP3102951A1 (en) * | 2014-02-07 | 2016-12-14 | MedImmune, LLC | Novel assay to detect human periostin |
WO2015126750A1 (en) * | 2014-02-19 | 2015-08-27 | Array Biopharma Inc. | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO TREATMENT WITH A CRTh2 INHIBITOR |
WO2015127405A2 (en) * | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
BR112016023238A2 (pt) | 2014-04-11 | 2017-10-17 | Novartis Ag | processos de tratamento seletivo de asma usando antagonistas de il-13 |
TW201628647A (zh) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗-il4-il13雙特異性抗體 |
MA40164A (fr) * | 2014-06-27 | 2017-05-03 | Sanofi Sa | Anticorps bispécifiques anti-il4-il13 |
EA034864B1 (ru) | 2014-09-08 | 2020-03-31 | Сефалон, Инк. | Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой |
EP3194446B1 (en) * | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | 抗インターロイキン−33抗体及びその使用 |
CN107109494B (zh) * | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
MX2017006864A (es) | 2014-12-23 | 2017-08-28 | Genentech Inc | Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia. |
MX2017008748A (es) | 2015-01-09 | 2017-11-17 | Medimmune Llc | Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana. |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
EP3371225A2 (en) | 2015-11-04 | 2018-09-12 | AstraZeneca AB | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
US20200216900A1 (en) * | 2016-02-17 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Nasal biomarkers of asthma |
BR112018071276A2 (pt) | 2016-04-27 | 2019-02-12 | Pfizer Inc. | anticorpos anti-il-33, composições, métodos e usos dos mesmos |
CN114617962A (zh) | 2016-04-27 | 2022-06-14 | 艾伯维公司 | 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法 |
SI3528838T1 (sl) * | 2016-09-23 | 2023-10-30 | F. Hoffmann-La Roche Ag | Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa |
CA3051700A1 (en) | 2017-02-10 | 2018-08-16 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
KR102417088B1 (ko) | 2018-02-09 | 2022-07-07 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
EP3769089A4 (en) * | 2018-03-19 | 2022-08-03 | BioVentures, LLC | PERIOSTIN ANTIBODIES AND METHODS OF USE THEREOF |
CN108977511A (zh) * | 2018-07-03 | 2018-12-11 | 张罗 | 检测鼻腔脱落细胞中cst1基因表达量的方法及应用 |
CN111415728A (zh) * | 2019-11-25 | 2020-07-14 | 刘雷 | 基于cnn和gan的ct图像数据自动分类方法及设备 |
CN115605507A (zh) | 2020-03-13 | 2023-01-13 | 基因泰克公司(Us) | 抗白介素-33抗体及其用途 |
CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
Family Cites Families (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4578349A (en) | 1982-04-08 | 1986-03-25 | Abbott Laboratories | Immunoassay for carcinoembryonic antigen (CEA) |
US4818709A (en) | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US6013772A (en) | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
US5231009A (en) | 1986-08-13 | 1993-07-27 | Molecular Diagnostics, Inc. | Cdnas coding for members of the carcinoembryonic antigen family |
US5122599A (en) | 1986-08-13 | 1992-06-16 | Molecular Diagnostics, Inc. | CDNAS coding for members of the carcinoembryonic antigen family |
ATE96168T1 (de) | 1986-08-13 | 1993-11-15 | Miles Inc | Karzinoembryonisches antigen kodierende cdns. |
US5274087A (en) | 1986-08-13 | 1993-12-28 | Molecular Diagnostics, Inc. | cDNA coding for carcinoembryonic antigen (CEA) |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
GB8800078D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
JPH05268982A (ja) | 1992-03-27 | 1993-10-19 | Hoechst Japan Ltd | 骨形成作用を有する新規な蛋白質およびその製造法 |
US5596072A (en) | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
JPH07508179A (ja) | 1992-08-21 | 1995-09-14 | シェリング・コーポレーション | ヒトインターロイキン−13 |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
WO1995011923A1 (en) | 1993-10-29 | 1995-05-04 | Dana-Farber Cancer Institute, Inc. | A novel tumor marker and novel method of isolating same |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
NZ295022A (en) | 1994-10-05 | 1999-04-29 | Immunex Corp | Lerk-6 polypeptide derivatives, proteins, dna and host cells thereof |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE19614062A1 (de) | 1996-04-09 | 1997-10-16 | Bayer Ag | Verfahren zur kontinuierlichen Herstellung von Diarylcarbonaten |
US20060073133A1 (en) * | 1997-04-02 | 2006-04-06 | Kikly Kristine K | Sialoadhesin factor-3 antibodies |
EP1017807A1 (en) | 1997-05-29 | 2000-07-12 | Board Of Regents The University Of Texas System | Osf2/cbfa1 compositions and methods of use |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
EP1000084A4 (en) | 1997-07-08 | 2003-03-26 | Human Genome Sciences Inc | 123 PROTEIN SEPARATED BY HUMAN |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
EP2180007B2 (en) | 1998-04-20 | 2017-08-30 | Roche Glycart AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6482403B1 (en) | 1998-05-29 | 2002-11-19 | Heska Corporation | Caniney IL-13 immunoregulatory proteins and uses thereof |
HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU2750800A (en) | 1999-02-01 | 2000-08-18 | Amgen Canada Inc. | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
BR0014480A (pt) | 1999-10-04 | 2002-06-11 | Medicago Inc | Método para regular a transcrição de genes estranhos |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
EP1270595B1 (en) | 2000-03-03 | 2008-07-23 | Kyowa Hakko Kogyo Co., Ltd. | Anti ccr4 antibody and its fragment |
US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
JP4534092B2 (ja) | 2000-09-08 | 2010-09-01 | 第一三共株式会社 | 心不全治療剤 |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP2027867A1 (en) | 2000-10-20 | 2009-02-25 | Genetics Institute, LLC | Method and composition for inhibition of tumor growth and enhancing an immune response |
WO2002033073A1 (fr) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agoniste degrade |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002239422B2 (en) | 2000-11-30 | 2006-12-07 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
US20030152956A1 (en) * | 2000-12-26 | 2003-08-14 | Noriko Ohtani | Method of examining allergic disease |
US6596240B2 (en) | 2001-01-12 | 2003-07-22 | Porex Corporation | Pipette tip for easy mounting and ejecting from a pipette |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
EP2000148A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of prostate cancer |
US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2457065A1 (en) | 2001-08-13 | 2003-02-27 | Dana-Farber Cancer Institute, Inc. | Periostin-based diagnostic assays |
PT1449850E (pt) | 2001-08-31 | 2011-02-02 | Kyowa Hakko Kirin Co Ltd | Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos |
US7384736B2 (en) | 2001-09-06 | 2008-06-10 | Decode Genetics Ehf. | Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease |
GB0123951D0 (en) * | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
EP1578912A4 (en) | 2001-10-26 | 2007-12-26 | Centocor Inc | IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES |
WO2003038055A2 (en) | 2001-10-31 | 2003-05-08 | Mds Proteomics, Inc. | Proteins involved in regulation of adipocytes and uses related thereto |
WO2003072827A1 (en) | 2001-10-31 | 2003-09-04 | Children's Hospital Medical Center | Method for diagnosis and treatment of rheumatoid arthritis |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003223497A1 (en) | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
AU2003236022A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
DE20205500U1 (de) | 2002-04-09 | 2002-07-11 | Hurth Ursula | Tampon |
ES2362419T3 (es) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. |
CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
AU2003226065B2 (en) | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
SE522615C2 (sv) | 2002-07-09 | 2004-02-24 | Martin Tiberg Med Tiberg Techn | En metod och ett system för biometrisk identifiering eller verifiering. |
JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B8 (pt) | 2002-12-16 | 2023-02-28 | Genentech Inc | Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
DE10304350B3 (de) | 2003-02-03 | 2004-06-09 | Sabeu Kunststoffwerk Northeim Gmbh | Behälterverschluß |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
WO2004091510A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Recombinant il-9 antibodies and uses thereof |
US8394379B2 (en) * | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
CA2524567A1 (en) | 2003-05-23 | 2004-12-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumors of glial origin |
WO2004106495A2 (en) | 2003-05-29 | 2004-12-09 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
EP2327796A1 (en) | 2003-06-10 | 2011-06-01 | The Trustees Of Boston University | Detection methods for disorders of the lung |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
WO2005019471A2 (en) | 2003-08-13 | 2005-03-03 | Temple University Of The Commonwealth System Of Higher Education | Periostin-like factor: compositions and methods for making and using the same |
US20050053549A1 (en) * | 2003-09-10 | 2005-03-10 | Aperon Biosystems Corp. | Method for treating airway disorders |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
SG10202008722QA (en) | 2003-11-05 | 2020-10-29 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
CA2550651C (en) | 2003-12-23 | 2018-01-23 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
KR100635540B1 (ko) | 2004-10-12 | 2006-10-18 | 경북대학교 산학협력단 | 신규한 염증성 질환의 예방 또는 치료용 약학적 조성물 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DE602005025525D1 (de) * | 2004-11-17 | 2011-02-03 | Amgen Inc | Vollständige humane monoklonale antikörper gegen il-13 |
GB2430883B (en) | 2005-09-30 | 2008-03-19 | Cambridge Antibody Tech | Interleukin-13 antibody composition |
WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US8017119B2 (en) | 2005-12-28 | 2011-09-13 | Daiichi Sankyo Company, Ltd. | Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved |
BRPI0620747A2 (pt) | 2005-12-28 | 2011-11-22 | Univ Osaka | anticorpo contra periostina, e uma composição farmacêutica compreendendo este para prevenir ou tratar uma doença na qual está envolvida periostina |
GB0600488D0 (en) | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
US7947648B2 (en) | 2006-01-11 | 2011-05-24 | Aerovance, Inc. | Methods for treating asthma in human and non human primates using IL-4 mutant compositions |
AU2007218158A1 (en) * | 2006-02-22 | 2007-08-30 | Philogen Spa | Vascular tumor markers |
US20070292936A1 (en) | 2006-05-09 | 2007-12-20 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20070275925A1 (en) | 2006-05-17 | 2007-11-29 | Regents Of The University Of California | Asthma diagnosis and therapy |
WO2008016356A2 (en) | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
ES2817756T3 (es) | 2006-09-08 | 2021-04-08 | Abbvie Bahamas Ltd | Proteínas de unión a interleuquina-13 |
EP2087113A2 (en) * | 2006-10-11 | 2009-08-12 | Fusion Antibodies Limited | Combination therapy |
JP4369468B2 (ja) | 2006-12-15 | 2009-11-18 | 日本分光株式会社 | 不可逆反応測定方法 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
BRPI0806313A2 (pt) | 2007-01-09 | 2011-09-06 | Wyeth Corp | Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida |
UA102994C2 (ru) | 2007-03-22 | 2013-09-10 | Дженентек, Инк. | АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ |
TW200848429A (en) * | 2007-04-23 | 2008-12-16 | Wyeth Corp | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
EP2777710A1 (en) | 2007-04-30 | 2014-09-17 | Glaxosmithkline LLC | Methods for administering anti-IL-5 antibodies |
WO2008140455A1 (en) | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CN101888855A (zh) | 2007-06-27 | 2010-11-17 | 阿斯比奥制药株式会社 | 含有由抗骨膜素的外显子-17编码的肽的抗体的癌症治疗剂 |
AU2008274938A1 (en) | 2007-07-11 | 2009-01-15 | Aerovance, Inc. | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
US8420310B2 (en) | 2008-06-05 | 2013-04-16 | Saga University | Method for detection of idiopathic interstitial pneumonia |
US20110130335A1 (en) | 2008-07-18 | 2011-06-02 | MitsubishiChemical Medience Corporation | Therapeutic agent and test agent for disease with myocardial necrosis |
RU2011113405A (ru) * | 2008-09-08 | 2012-10-20 | Оттава Хоспитл Рисерч Инститьют (Ca) | Регенерация поджелудочной железы, индуцированная периостином |
JP5522717B2 (ja) * | 2008-09-19 | 2014-06-18 | 国立大学法人佐賀大学 | アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法 |
US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
FR2946349B1 (fr) * | 2009-06-03 | 2013-10-04 | Synarc Sas | Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine |
MY188365A (en) | 2010-12-16 | 2021-12-06 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
US9347954B2 (en) | 2011-09-06 | 2016-05-24 | Shino-Test Corporation | Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same |
-
2011
- 2011-12-16 MY MYPI2013001957A patent/MY188365A/en unknown
- 2011-12-16 CN CN201510591098.7A patent/CN105175542B/zh active Active
- 2011-12-16 MX MX2017015918A patent/MX371228B/es unknown
- 2011-12-16 RU RU2013132733/15A patent/RU2578468C2/ru active
- 2011-12-16 EP EP18166030.9A patent/EP3447491A3/en active Pending
- 2011-12-16 EP EP11848523.4A patent/EP2652498B1/en active Active
- 2011-12-16 CN CN202011057363.0A patent/CN112168962A/zh active Pending
- 2011-12-16 KR KR1020147035860A patent/KR101615474B1/ko active IP Right Grant
- 2011-12-16 WO PCT/US2011/065410 patent/WO2012083132A2/en active Application Filing
- 2011-12-16 NZ NZ609493A patent/NZ609493A/en unknown
- 2011-12-16 NZ NZ713202A patent/NZ713202A/en unknown
- 2011-12-16 RU RU2015139698A patent/RU2737245C2/ru active
- 2011-12-16 MX MX2013006712A patent/MX352789B/es active IP Right Grant
- 2011-12-16 KR KR1020147035863A patent/KR101616260B1/ko active IP Right Grant
- 2011-12-16 SG SG2013040431A patent/SG190885A1/en unknown
- 2011-12-16 JP JP2013544814A patent/JP6005657B2/ja active Active
- 2011-12-16 TW TW108127617A patent/TWI732259B/zh active
- 2011-12-16 KR KR1020167010543A patent/KR101923282B1/ko active IP Right Grant
- 2011-12-16 CA CA2817380A patent/CA2817380C/en active Active
- 2011-12-16 TW TW100146961A patent/TWI666447B/zh active
- 2011-12-16 TW TW106106464A patent/TW201732294A/zh unknown
- 2011-12-16 SG SG10201401763SA patent/SG10201401763SA/en unknown
- 2011-12-16 BR BR112013013460A patent/BR112013013460A8/pt active Search and Examination
- 2011-12-16 CN CN201510591057.8A patent/CN105169390A/zh active Pending
- 2011-12-16 SG SG10201401746TA patent/SG10201401746TA/en unknown
- 2011-12-16 CN CN201180067674.8A patent/CN103688171B/zh active Active
- 2011-12-16 BR BR122020012255-2A patent/BR122020012255B1/pt active IP Right Grant
- 2011-12-16 AR ARP110104747A patent/AR084342A1/es unknown
- 2011-12-16 KR KR1020137013288A patent/KR101615420B1/ko active IP Right Grant
- 2011-12-16 TW TW108100885A patent/TWI708944B/zh active
- 2011-12-16 US US13/328,830 patent/US20120156194A1/en not_active Abandoned
- 2011-12-16 AU AU2011343570A patent/AU2011343570B2/en active Active
- 2011-12-16 CA CA3040095A patent/CA3040095C/en active Active
-
2013
- 2013-04-24 ZA ZA2013/02979A patent/ZA201302979B/en unknown
- 2013-06-09 IL IL226821A patent/IL226821B/en active IP Right Grant
- 2013-09-09 US US14/021,698 patent/US9684000B2/en active Active
- 2013-09-09 US US14/021,947 patent/US9995755B2/en active Active
-
2014
- 2014-11-25 JP JP2014237322A patent/JP6502069B2/ja active Active
-
2015
- 2015-08-14 JP JP2015160118A patent/JP6297526B2/ja active Active
-
2016
- 2016-03-29 HK HK16103588.4A patent/HK1215711A1/zh unknown
- 2016-04-05 HK HK16103827.5A patent/HK1215857A1/zh unknown
-
2017
- 2017-08-14 JP JP2017156349A patent/JP2018009998A/ja active Pending
-
2018
- 2018-05-29 US US15/992,115 patent/US11226341B2/en active Active
- 2018-10-10 IL IL262278A patent/IL262278B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
EA201290883A1 (ru) | Способы диагностики и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака | |
MX2013000674A (es) | Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer. | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
EA201491221A1 (ru) | Новые молекулы, ингибирующие jnk, для лечения различных болезней | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
WO2011141823A3 (en) | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists | |
EA201101568A1 (ru) | Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta | |
IN2015DN00450A (es) | ||
MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
WO2012145535A3 (en) | Animal model of human cancer and methods of use | |
MX2014000066A (es) | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. | |
MX2014005749A (es) | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
WO2011106785A3 (en) | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith | |
WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
MX343366B (es) | Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica. | |
MX2011007373A (es) | Metodos para identificar pacientes que responderan bien a tratamiento para el cancer. |